Hangzhou Tigermed Consulting (03347) plans to buy back RMB 500 million to 1 billion worth of A shares.

Hangzhou Tigermed Consulting (03347) announced that, in order to promote the healthy and stable long-term development of the company, enhance investor confidence in the company, safeguard the interests of a wide range of investors, and further establish a sound long-term incentive mechanism, based on the recognition of the company's development prospects and intrinsic value, the company intends to use its own funds or raise funds through centralized competitive bidding or other ways permitted by laws and regulations to repurchase some of the company's A shares. This repurchase will be used for the implementation of A-share equity incentive plans or A-share employee share ownership plans, as well as to reduce the company's registered capital. The total amount of funds for this repurchase of shares shall not be less than 500 million yuan and not exceed 1 billion yuan, with the share price not exceeding 60.00 yuan per share (including 60.00 yuan per share). The number of shares used for employee stock ownership plans or equity incentives shall not exceed 60% of the total repurchase quantity, while the number of shares used for cancellation to reduce registered capital shall not be less than 40% of the total repurchase quantity.